MX358514B - Compuestos para tratar la atrofia muscular espinal. - Google Patents
Compuestos para tratar la atrofia muscular espinal.Info
- Publication number
- MX358514B MX358514B MX2014011233A MX2014011233A MX358514B MX 358514 B MX358514 B MX 358514B MX 2014011233 A MX2014011233 A MX 2014011233A MX 2014011233 A MX2014011233 A MX 2014011233A MX 358514 B MX358514 B MX 358514B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- muscular atrophy
- spinal muscular
- treating spinal
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614932P | 2012-03-23 | 2012-03-23 | |
| PCT/US2013/031232 WO2013142236A1 (en) | 2012-03-23 | 2013-03-14 | Compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014011233A MX2014011233A (es) | 2014-11-25 |
| MX358514B true MX358514B (es) | 2018-08-24 |
Family
ID=49223223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011233A MX358514B (es) | 2012-03-23 | 2013-03-14 | Compuestos para tratar la atrofia muscular espinal. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9914722B2 (https=) |
| EP (1) | EP2828247B1 (https=) |
| JP (1) | JP6219921B2 (https=) |
| KR (1) | KR102109992B1 (https=) |
| CN (1) | CN104470909B (https=) |
| BR (1) | BR112014023483B1 (https=) |
| CA (1) | CA2868026C (https=) |
| EA (1) | EA028382B1 (https=) |
| MX (1) | MX358514B (https=) |
| WO (1) | WO2013142236A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2865957C (en) | 2012-03-01 | 2020-02-11 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| CA2894992A1 (en) * | 2012-12-24 | 2014-07-03 | Ramot At Tel-Aviv University Ltd. | Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same |
| EP3035935B1 (en) | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Compounds for use in the prophylaxis and treatment of cancer |
| US10195202B2 (en) | 2013-12-19 | 2019-02-05 | Ptc Therapeutics, Inc. | Methods for modulating the amount of RNA transcripts |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| TN2017000508A1 (en) | 2015-06-26 | 2019-04-12 | Takeda Pharmaceuticals Co | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| EP3366679B1 (en) | 2015-10-20 | 2021-03-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EA201800367A1 (ru) | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| JP2020523365A (ja) | 2017-06-14 | 2020-08-06 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを改変する方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| JP7312749B2 (ja) | 2017-08-04 | 2023-07-21 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングをモジュレートする方法および組成物 |
| JPWO2019168170A1 (ja) * | 2018-03-02 | 2021-03-04 | 国立大学法人 長崎大学 | クロモン誘導体及びアミロイド関連疾患診断用組成物 |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| CN112469707B (zh) | 2018-06-27 | 2024-06-21 | 利伯纳生物科学株式会社 | 脊髓性肌萎缩症的预防剂或治疗剂 |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| HRP20240935T1 (hr) | 2018-06-27 | 2024-11-22 | Ptc Therapeutics, Inc. | Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti |
| WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7649257B2 (ja) | 2019-05-13 | 2025-03-19 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| KR102823820B1 (ko) * | 2022-09-01 | 2025-06-23 | 단국대학교 천안캠퍼스 산학협력단 | 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물 |
| WO2024249554A1 (en) * | 2023-05-30 | 2024-12-05 | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | Multitarget small molecule inhibitors and uses thereof |
| AU2024286618A1 (en) * | 2023-06-09 | 2025-10-30 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH479607A (de) | 1967-02-27 | 1969-10-15 | Geigy Ag J R | Verfahren zur Herstellung von Areno-oxazinonverbindungen |
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| GB1296469A (https=) * | 1970-02-05 | 1972-11-15 | ||
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| US5278174A (en) | 1990-06-04 | 1994-01-11 | Scios Nova, Inc. | Sigma binding site agents |
| AU4231293A (en) | 1992-05-13 | 1993-12-13 | E.I. Du Pont De Nemours And Company | Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides |
| EP0625522B1 (en) * | 1993-05-18 | 1998-08-19 | Takeda Chemical Industries, Ltd. | Benzopyran derivatives and their use |
| US5597922A (en) | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
| US6630488B1 (en) | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
| EP1857443B1 (en) | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| WO2003104216A1 (en) | 2002-06-10 | 2003-12-18 | Acadia Pharmaceuticals Inc. | Urotensin ii receptor modulators |
| JP4646626B2 (ja) | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド３−キナーゼβの阻害 |
| CN101260104A (zh) * | 2002-08-16 | 2008-09-10 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
| WO2004047766A2 (en) | 2002-11-25 | 2004-06-10 | Kaloidis Antonia C | Treatment for sma disease |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| WO2004113335A2 (en) | 2003-06-20 | 2004-12-29 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| AU2004289303A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| ATE373659T1 (de) | 2004-05-04 | 2007-10-15 | Warner Lambert Co | Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel |
| WO2006045010A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| CA2595477A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| US20090123563A1 (en) | 2005-02-07 | 2009-05-14 | Novo Nordisk A/S | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand |
| CA2617213C (en) * | 2005-07-29 | 2014-01-28 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| WO2008013997A2 (en) | 2006-07-27 | 2008-01-31 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| ES2539828T3 (es) | 2007-09-14 | 2015-07-06 | Naturewise Biotech & Medicals Corporation | Compuestos para la inhibición de la histona de acetilasa |
| US8008344B2 (en) | 2007-09-14 | 2011-08-30 | NatureWise Biotech and Medicals Corporation | Compounds for the inhibition of histone deacetylase |
| CA2715796C (en) | 2008-03-06 | 2015-04-28 | Rottapharm S.P.A. | 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| US8932818B2 (en) | 2008-08-13 | 2015-01-13 | Ptc Therapeutics, Inc. | Screening assays for compounds that modulate programmed ribosomal frameshifting |
| WO2010048273A2 (en) | 2008-10-21 | 2010-04-29 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
| CN101851220A (zh) * | 2009-04-03 | 2010-10-06 | 彦臣生技药品股份有限公司 | 异戊二烯类黄酮化合物及其用途 |
| CN102812014B (zh) * | 2009-10-30 | 2016-01-20 | 多美恩医疗公司 | 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途 |
| PH12012500901A1 (en) | 2009-11-05 | 2016-08-05 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| CN102812023A (zh) | 2010-01-13 | 2012-12-05 | 韩国巴斯德研究所 | 抗感染吡啶并(1,2-a)嘧啶类 |
| WO2011130515A1 (en) | 2010-04-14 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| HRP20190128T1 (hr) | 2011-05-04 | 2019-03-08 | Rhizen Pharmaceuticals S.A. | Novi spojevi kao modulatori protein kinaza |
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2865957C (en) | 2012-03-01 | 2020-02-11 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
-
2013
- 2013-03-14 CA CA2868026A patent/CA2868026C/en active Active
- 2013-03-14 CN CN201380027139.9A patent/CN104470909B/zh active Active
- 2013-03-14 US US14/386,524 patent/US9914722B2/en active Active
- 2013-03-14 JP JP2015503291A patent/JP6219921B2/ja active Active
- 2013-03-14 BR BR112014023483-3A patent/BR112014023483B1/pt active IP Right Grant
- 2013-03-14 EA EA201491766A patent/EA028382B1/ru not_active IP Right Cessation
- 2013-03-14 MX MX2014011233A patent/MX358514B/es active IP Right Grant
- 2013-03-14 EP EP13763520.7A patent/EP2828247B1/en active Active
- 2013-03-14 KR KR1020147029409A patent/KR102109992B1/ko active Active
- 2013-03-14 WO PCT/US2013/031232 patent/WO2013142236A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015517988A (ja) | 2015-06-25 |
| CA2868026A1 (en) | 2013-09-26 |
| CN104470909A (zh) | 2015-03-25 |
| EP2828247A4 (en) | 2015-12-16 |
| BR112014023483B1 (pt) | 2022-05-10 |
| EA028382B1 (ru) | 2017-11-30 |
| MX2014011233A (es) | 2014-11-25 |
| BR112014023483A2 (https=) | 2017-06-20 |
| KR102109992B1 (ko) | 2020-05-13 |
| EA201491766A1 (ru) | 2015-03-31 |
| CN104470909B (zh) | 2018-04-24 |
| HK1202527A1 (en) | 2015-10-02 |
| US9914722B2 (en) | 2018-03-13 |
| WO2013142236A1 (en) | 2013-09-26 |
| KR20140135840A (ko) | 2014-11-26 |
| CA2868026C (en) | 2021-02-16 |
| US20150080383A1 (en) | 2015-03-19 |
| EP2828247B1 (en) | 2019-01-16 |
| JP6219921B2 (ja) | 2017-10-25 |
| EP2828247A1 (en) | 2015-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX358514B (es) | Compuestos para tratar la atrofia muscular espinal. | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| MX357834B (es) | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. | |
| MX352962B (es) | Compuestos para tratar atrofia muscular espinal. | |
| UY33627A (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| MX374399B (es) | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| CL2012003385A1 (es) | Tratamiento para la incontinencia. | |
| UY35787A (es) | Composiciones útiles para tratar trastornos relacionados con kit | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| CL2014002640A1 (es) | Compuestos pirrolidin, piperidin o azepan sustituidos, inhibidores de met-ap2; procedimiento para prepararlos; y medicamento que los contiene. | |
| CY1120204T1 (el) | Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο | |
| MX359769B (es) | Metodos para descelularizar huesos. | |
| CR20150067A (es) | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n | |
| GEP201706710B (en) | Imidazopyridazine derivatives as gabaa receptor modulators | |
| MX2015003701A (es) | Composiciones para tratamiento. | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
| DOP2015000060A (es) | Profármacos de aminoquinazolina inhibidora de cinasa | |
| BR112014026326A2 (pt) | composição para tratamento de distúrbios metabólicos | |
| MX2015006337A (es) | Metodos y composiciones para tratar enfermedades neurodegenerativas. | |
| CR20150070A (es) | Pirrolopirazoles como bloqueadores del canal de calcio tipo n | |
| LT2812013T (lt) | Kompozicija, skirta džs gydymui | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |